Altasciences

Name

Altasciences

Legal name

Altasciences

Website

https://altasciences.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) and CDMO Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Testing Laboratories and Services (54138), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Contract research organization
• Early-phase drug development
• Preclinical safety testing
• Clinical pharmacology trials
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Laval

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Preclinical Services: Contract research services for preclinical safety evaluation including GLP and non-GLP toxicology studies, safety pharmacology, pharmacokinetics/pharmacodynamics, and specialized preclinical studies across multiple species for small and large molecules.
2. Clinical Research Services: Clinical pharmacology trials from first-in-human through Phase II, including proof-of-concept studies, bioavailability/bioequivalence, specialized assessments (CNS, topical, inhalation), and NDA-enabling studies conducted across three clinical pharmacology units with 580+ beds.
3. Bioanalytical Services: Bioanalytical method development and validation, LC-MS/MS analysis, ligand binding assays, immunogenicity testing, biomarker analysis, flow cytometry, and sample management services supporting preclinical through Phase IV studies.
4. Manufacturing and Analytical Services (CDMO): Pharmaceutical contract development and manufacturing including formulation development, clinical supply manufacturing (Phase I-III), commercial manufacturing, ICH stability testing, analytical method development and validation, and finished product release testing.
5. Research Support Services: Complementary CRO services including regulatory affairs, biostatistics, data management, medical writing, clinical monitoring, project management, and program management to support integrated drug development programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Altasciences is an integrated early-phase contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering biopharmaceutical companies preclinical safety testing, clinical pharmacology (Phase I to Phase II), bioanalysis, research support services, and manufacturing and analytical services under a single integrated Acceleration Platform that reduces program timelines by up to 40%.

Product overview

Altasciences is an integrated early-phase contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering comprehensive drug development services. The company operates as a unified platform combining multiple service modules: Preclinical Services for safety assessment, Clinical Services for Phase I-II trials, Manufacturing and Analytical Services for pharmaceutical development, Bioanalytical Services for laboratory analysis, and Research Support Services for clinical operations. The Acceleration Platform serves as the core integrating architecture, enabling seamless transitions between preclinical through proof-of-concept phases. Additional specialized offerings include CNS Clinical Trials, Topical/Transdermal Studies, Inhalation Studies, Pain Models, PBMC Isolation, and Cell and Gene Therapy Development. The company's Tell Us Once commitment and dedicated Program Management services connect these modules to deliver end-to-end drug development with a single partner approach.

Differentiator

Problem solved

Functional benefit

Products and services

• Preclinical Services
• Clinical Services
• Manufacturing and Analytical Services
• Bioanalytical Services
• Research Support Services
• Cell and Gene Therapy Development
• CNS Clinical Trials
• Topical and Transdermal Studies
• Inhalation Studies

Quantifiable outcome

• 24% of all 2025 FDA novel drug approvals (11 of 46) supported by Altasciences' integrated approach
• +5 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

Five partnerships are on record, tiered core and minor.

• CertaracoreStrategic or Co-development Partner · 7 May 2026Strategic partnership to integrate Certara's biosimulation technology and model-informed drug development (MIDD) services with Altasciences' drug development Acceleration Platform. The collaboration aims to help biotech sponsors establish proof of mechanism earlier, optimize study designs, and make more informed go/no-go decisions, addressing the industry challenge where fewer than half of preclinical candidates reach first-in-human trials. The partnership aligns with FDA's advancing guidance supporting adaptive, data-driven drug development approaches.
• VoxCell BioInnovationcoreStrategic or Co-development Partner · 31 July 2025Strategic collaboration to leverage VoxCell's 3D bioprinting and human-like tissue modeling technology to enhance preclinical research and accelerate drug development timelines. The partnership initially focuses on drug screening for ocular indications before expanding to other therapeutic areas. Both companies aim to reduce translational gaps and offer more predictive preclinical testing environments to pharmaceutical and biotechnology clients.
• Cambridge CognitioncoreTechnology or IntegrationPartnership with Cambridge Cognition, a global leader in digital neuroscience technology, to deliver validated, non-invasive cognitive test batteries for CNS clinical trials. The partnership provides access to validated cognitive assessment tools covering attention, memory, executive function, and psychomotor performance for strategic cognitive testing in first-in-human and proof-of-concept studies.
• Cognitive Research Corporation (CRC)coreTechnology or IntegrationPartnership with Cognitive Research Corporation (CRC) offering state-of-the-art driving simulation studies through Altasciences' 12 on-site driving simulators. The partnership provides accurate, reproducible data comparable in sensitivity to on-road testing for assessing drug effects on real-world driving performance, enabling sponsors to evaluate CNS-active compounds' impact on driving ability.
• Steel TherapeuticsminorStrategic or Co-development PartnerSelected by Steel Therapeutics to conduct a pivotal toxicology study for Fizurex™, a topical therapy for anal fissures, at Altasciences' facility in Missouri. The study supports Steel's effort to seek regulatory approval for Fizurex™ with an IND application planned for early 2026.

Scale indicators12 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• WuXi AppTec: Global CRO/CDMO with end-to-end discovery, preclinical, clinical, and manufacturing services, often viewed as a comparable integrated platform, though at significantly larger scale and with a broader geographic footprint.
• ICON plc: Major global CRO offering clinical and bioanalytical services spanning Phase I-IV, directly competing for biotech and pharma early-phase work as part of a much broader services portfolio.
• IQVIA: Largest full-service CRO with deep clinical, real-world evidence, and technology capabilities; overlaps with Altasciences in early-phase clinical pharmacology and bioanalysis but operates as a broad incumbent across the entire drug development lifecycle.
• Syneos Health: Large clinical and commercial CRO with Phase I-IV capabilities, competing for early-phase engagements and providing a benchmark for mid-to-large CRO operating models.
• Parexel: Large global CRO providing Phase I-IV clinical, biostatistics, and regulatory services, overlapping with Altasciences in early-phase clinical pharmacology and bioanalytical work for biotech sponsors.
• Labcorp (Covance): Diversified clinical and preclinical CRO plus central laboratory, competing with Altasciences in early-phase clinical, bioanalytical, and central lab services for global biopharma sponsors.

Direct peers

• Worldwide Clinical Trials: Mid-size CRO with comparable early-phase clinical pharmacology capabilities and CNS expertise, competing head-to-head for the same biotech sponsor relationships.
• Medpace: Mid-size full-service CRO with strong mid-cap biotech focus and a tightly integrated operating model, often cited alongside Altasciences as a differentiated mid-size competitor in early- and mid-phase clinical work.
• BioAgilytix Labs: Specialized bioanalytical CRO supporting large-molecule PK, immunogenicity, and biomarker work, directly comparable to Altasciences' 685+ assay bioanalytical platform serving similar biotech and pharma sponsors.
• Charles River Laboratories: Direct peer in preclinical safety assessment and early-stage drug development, with a comparable end-to-end offering from preclinical through manufacturing, competing for the same biotech and pharma sponsors in North America and globally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCIoBiLT0jCW0M5RJg5iba-g
• LinkedInlinkedin.com/company/altasciences-clinical-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altasciences